Ladenburg Thalmann Financial Services’s Coherus Oncology CHRS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$9K	Sell	509 -292	-36%	-$5.38K	﹤0.01%	4519
2019 Q3	$17K	Buy	+801	New	+$16K	﹤0.01%	4124
2017 Q4	–	Sell	-12,600	Closed	-$168K	–	5035
2017 Q3	$168K	Buy	12,600 +10,491	+497%	+$139K	﹤0.01%	2233
2017 Q2	$31K	Buy	2,109 +2,000	+1,835%	+$38.5K	﹤0.01%	3328
2017 Q1	$2K	Sell	109 -263	-71%	-$6.47K	﹤0.01%	4546
2016 Q4	$10K	Hold	372	–	–	﹤0.01%	3874
2016 Q3	$10K	Buy	+372	New	+$10.1K	﹤0.01%	3803

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CHRS Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Coherus Oncology (CHRS) stake by 36% in Q4 2019, selling an estimated $5.38K and leaving 509 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #4519.

Ladenburg Thalmann Financial Services first reported a position in CHRS in Q3 2016 and has held it in 7 quarters since. The position peaked at $168K in Q3 2017. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

Ladenburg Thalmann Financial Services held 509 shares of Coherus Oncology worth $9K as of Q4 2019.
Ladenburg Thalmann Financial Services sold 292 Coherus Oncology shares in Q4 2019, an estimated $5.38K.
Coherus Oncology made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4519 holding.
Ladenburg Thalmann Financial Services first reported a position in Coherus Oncology in Q3 2016 and has held it in 7 quarters since.
Ladenburg Thalmann Financial Services's Coherus Oncology position peaked at $168K in Q3 2017.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.